Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Polycystic ovary syndrome (PCOS) is the most common Female endocrine disorder , with a
prevalence ranging between 6% to10% based on the National Institutes of Health (NIH) criteria
and when the broader Rotterdam criteria are applied it reaches as high as 15%. Typically,
PCOS can identify during the early adolescence. Insulin resistance is a common finding in the
obese women with PCOS. It is most prevalent and severe in PCOS phenotype involving
hyperandrogenism and chronic anovulation. Women with PCOS who have regular cycles are
metabolically less abnormal. Acanthosis nigricans (AN) is a dermatosis characterized by
velvety, papillomatous, brownish-black, hyperkeratotic plaques, typically of the
intertriginous surfaces and neck. Although AN is associated with malignancy, the recognition
of its more common connection to obesity and insulin resistance allows for diagnosis of
related disorders including type 2 diabetes, the metabolic syndrome, and polycystic ovary
syndrome. Significant improvements in ovulation and pregnancy rates as a result of clomiphene
treatment after metformin in women with clomiphene-resistant PCOS were reported in a popular
randomized, double-blind, placebo-controlled trial . The first pharmacological approach to
induction of ovulation in women with PCOS is clomiphene citrate